The Medicines Co. followed up its 26 August top-line readout for the Phase III ORION-11 trial of inclisiran with a full dataset that shows the short-interfering RNA (siRNA) therapy can offer LDL cholesterol-lowering capability similar to on-market PCSK9 inhibitors with twice-yearly dosing and a safety and tolerability profile similar to placebo.
Presenting the data at the European Society of Cardiology meeting on 2 September, The Medicines Co. asserted that inclisiran can be a market-disrupting LDL-C therapy that will address needs for...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?